bciintel.com exists to provide the clearest, most comprehensive window into the brain-computer interface industry. BCIs represent one of the most consequential frontiers in medicine — restoring communication to people with ALS, enabling movement in those with paralysis, and opening entirely new channels between mind and machine.
Our mission is to serve neuroscientists, clinicians, investors, regulators, patients, and curious minds who need to stay ahead of this rapidly evolving field. We track clinical trials, funding rounds, device specifications, FDA milestones, and research breakthroughs in real time.
bciintel.com uses advanced AI models to assist in drafting, summarizing, and structuring content at scale. All published articles undergo review by our editorial team for accuracy, context, and clinical correctness. We cite primary sources — including ClinicalTrials.gov, FDA MAUDE, arXiv, and peer-reviewed journals — and correct errors promptly.
Clinical trial data is sourced from ClinicalTrials.gov, published results, and company press releases. Device specifications are maintained from FDA 510(k) and PMA databases, IDE applications, and direct company communications. We always indicate the date of last update for any specification data.
Our agent monitors 20+ RSS feeds spanning JAMA, Nature Neuroscience, IEEE TNSRE, MedTechDive, STAT News, and BioWorld — plus targeted queries covering every major BCI company, trial registry update, and FDA action. Runs twice daily.
Stories that pass our relevance scoring (clinical significance, novelty, patient impact) are drafted by Claude, Anthropic's frontier model. Each article synthesizes the source material into concise, factual intelligence — citing primary sources and flagging uncertainty where it exists.
Qualifying articles are published directly to the site within hours. The device database, company profiles, funding dashboard, clinical trials tracker, and research hub are maintained through primary sources including FDA databases, ClinicalTrials.gov, and academic publications.
The fastest way to reach us is on X. We read every mention and DM. For partnerships, data submissions, corrections, and press enquiries, email us directly.
[email protected]@BCIintel